Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas

Launched by DARTMOUTH-HITCHCOCK MEDICAL CENTER · May 8, 2013

Keywords

ClinConnect Summary

This clinical trial is studying a specific molecule called microRNA-10b (miRNA-10b) to see how it behaves in patients with different types of brain tumors, including glioblastomas and other gliomas. Researchers believe that measuring the levels of miRNA-10b in tumor samples can help doctors better understand the cancer and predict how patients might respond to treatment. The study will also look at differences among various types of gliomas and test how effective a treatment that targets miRNA-10b might be in slowing tumor growth.

To participate in this trial, patients must be at least 18 years old and have a brain tumor that needs to be surgically removed. It’s important that the tumor is confirmed to be of glial origin (a type of brain cell) and falls into specific grades of severity (II, III, or IV). Participants will have their tumor, blood, and cerebrospinal fluid samples collected over a two-year period to analyze the levels of miRNA-10b. It’s worth noting that patients can still receive standard treatments for their condition while participating in this study. Overall, this trial aims to improve our understanding of brain tumors and potentially lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion/Exclusion Criteria:
• • 18 years of age
• • Brain tumor(s) to be resected for clinical reasons.
• • Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV.
• • Adequate tissue available for processing as determined by Pathology.
• • Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment.
• • Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.